Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CymaBay Therapeutics Inc. - Common Stock (NQ: CBAY )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CymaBay Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
CymaBay Therapeutics: Q1 Earnings Insights
Via Benzinga
CymaBay Therapeutics's Earnings Outlook
Via Benzinga
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 5/9
Via Investor Brand Network
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 5/2
Via Investor Brand Network
The Latest Analyst Ratings for CymaBay Therapeutics
Via Benzinga
Four Potential Breakout Stocks For The Rest Of The Week
In trading, there will always be elegance in simplicity. If your trading operation lacks a cadre of PhDs to crunch data like Renaissance Technologies or D.E. Shaw, simplicity will always trump... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023
Via Benzinga
Analyst Ratings for CymaBay Therapeutics
Via Benzinga
Preview: CymaBay Therapeutics's Earnings
Via Benzinga
Analyst Expectations for CymaBay Therapeutics's Future
Via Benzinga
Analyst Expectations for CymaBay Therapeutics's Future
Via Benzinga
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in... 
Via Benzinga
Why CymaBay Therapeutics Shares Are Rising
CymaBay Therapeutics Inc (NASDAQ: CBAY) shares are trading higher by 9.30% to $7.22 Tuesday morning. The company priced a public offering of common stock and pre-funded warrants at $7 per share and... 
Via Benzinga
CymaBay's New Seladelpar Two-Year Data Shows Improved Transplant-Free Survival
Via Benzinga
CymaBay Therapeutics: Q1 Earnings Insights
CymaBay Therapeutics (NASDAQ:CBAY) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
5 Most Expensive Health Care Stocks You Should Worry About
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
CymaBay Therapeutics: Q2 Earnings Insights
  CymaBay Therapeutics (NASDAQ:CBAY) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:06 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Outlook For CymaBay Therapeutics
  CymaBay Therapeutics (NASDAQ:CBAY) is set to give its latest quarterly earnings report on Thursday, 2022-08-11. Here's what investors need to know before the announcement. 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
79 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it... 
Via Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) gained 70% to $0.4900 after the company entered a sponsored research agreement under which in vivo preclinical data will be generated from Kiromic's Gamma... 
Via Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Vallon Pharmaceuticals (NASDAQ:VLON) shares moved upwards by 94.7% to $2.2 during Friday's pre-market session. The company's market cap stands at $14.9 million. 
Via Benzinga
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
CymaBay Therapeutics: Q4 Earnings Insights
CymaBay Therapeutics (NASDAQ:CBAY) reported its Q4 earnings results on Thursday, March 17, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.